Pehea e lawe ai iā Diagninid no ka maʻi diabetes?

Aia i loko o hoʻokahi papa:

ʻO ka repaglinide ma nā ʻōlelo o 100% waiwai - 0.5 mg, 1 mg a me 2 mg,

Poloxamer (type 188) 3 mg, 3 mg or 3 mg, meglumine 10 mg, 10 mg or 13 mg, lactose monohidate 47.8 mg, 47.55 mg or 61.7 mg, microcrystalline cellulose 33.7 mg, 33, 45 mg a i 45 mg, potassium polacryline 4 mg, 4 mg a i ʻole 4 mg, colloidal silicon dioxide 0.5 mg, 0.5 mg a i ka 0.7 mg, magnesium stearate 0.5 mg, 0.5 mg a 0.6 paha mg ma kēlā.

Lapaʻau lāʻau

ʻO ka lāʻau lapaʻau puʻupuʻu puʻupuʻu puʻu. Hoʻowalewale i ka hoʻokuʻu ana o ka insulin mai ka hana i nā peka beta o ka pancreas. Hoʻopili ia i nā ala hilinaʻi o ka ATP i nā membran o nā cell beta ma o ka huina o ka protein, kahi e hoʻoiho ai i ka depolarization o nā pū beta a me ka wehe i nā kanalula. Hoʻonui ka hoʻonui ʻana i ka wai kalaiwa no nā mea huna o ka insulin. I ka poʻe maʻi me ka maʻi diabetes mellitus type 2, kahi pane a ka insulinotropic i ka intake kaiʻai i mālama ʻia ma loko o 30 mau minuke ma hope o ka hoʻomaʻamaʻa ʻana o ka lāʻau. Hāʻawi kēia i ka emi o ka hōʻemi o ka glucose i ke koko i ka manawa holoʻokoʻa o ka ʻai kai. Ma kēia hihia, ke emi wikiwiki nei ka kaila o ka repaglinide i ka plasma, a me nā hola 4 ma hope o ka lawe ʻana i ka lāʻau, ʻike ʻia kahi haʻahaʻa o ka repaglinide i ka plasma o nā mea maʻi me ka maʻi maʻamau ʻo 2. Ke hoʻohana nei i ka repaglinide ma loko mai o ka nui o ka wai ma ka 0.5 a hiki i ka 4 mg, ua ʻike ʻia kahi emi ʻana o ka hopena o ka glucose.

Lapaʻau lāʻau

I ka wā e lawe laka ʻia, ʻoi ka nui o ka hoʻopili ʻana o ka repaglinide mai ka ʻeha gastrointestinal. ʻO ka manawa e hiki ai i ka lōʻihi loa o ka ʻike, ʻo ia ka hola 1. ʻO ka nui o ka bioavailability o ka repaglinide he 63% (ʻo ka mana variability he 11%). No ka mea, ke lawe ʻia nei ka titration o kahi hoʻomoʻi o ka repaglinide e like me ka pane ʻana i ka therapy, interindividual variability e pā ʻole i ka hopena o ka hopena.

Ka helu ʻokoʻa - 30 l. Ke kamaʻilio pū ʻana me nā protein plasma - 98%.

Hoʻohāʻokoʻa loa ia i ka puʻu ma o ka ʻike ʻana iā CYP3A4 i nā metabolite hana ʻole.

Hoʻokuʻu ʻia ia ma o nā ʻōpū ma o ka ʻōpū, e nā keiki - 8% i ke ʻano o nā metabolites, ma o nā ʻōpū - 1%. ʻO ka hapalua-ola kahi 1 hola.

ʻO ka hoʻohana ʻana i ka repaglinide ma nā maʻamau maʻamau i nā maʻi me nā hana heʻeha lēwa i hiki ke alakaʻi i kahi kiʻekiʻe o ka repaglinide a me nā metabolites ma mua o nā mea maʻi me nā hana ate maʻamau. Ma kēia noʻonoʻo, ua contraindicated ka hoʻohana ʻana o ka repaglinide i nā poʻe maʻi me ka hōʻeha ʻana i ka maʻi hepatic koʻikoʻi, a i ka poʻe maʻi me ka hana hepatic i hōʻeuʻeu ʻia i ka pale ʻana i ka leʻaleʻa pēpaglinide pono e hoʻohana pono me ka makaʻala. Pono hoʻi e hoʻonui pono ʻia ka pae ma waena o ka hoʻoponopono o ka hoʻoponopono ʻana i ka pane ʻana i ka pane.

ʻO ka mahele ma lalo o ka pīpī-paʻa o ka manawa (AUC) a me ke kao nui o ka repaglinide i ka plasma (C_max) nā mea like i ka poʻe maʻi me ka hana pūlima maʻamau a i nā mea maʻi me ka hana ʻole a lēʻalolo kahi maʻi molo a hōʻemi paha. I ka poʻe maʻi me ka maʻi mumuho koʻikoʻi, ʻike ʻia kahi hoʻonui o AUC a me C_maxakā naʻe, he mea nāwaliwali nāwaliwali ma waena o ka uila o ka repaglinide a me ka hoʻopiʻi creatinine i hōʻike ʻia. ʻIke ʻia he poʻe maʻi me ka hana renal impaired i ʻole ka hewa o ka hoʻoponopono ʻana i ka ma mua. Eia naʻe, ʻo ka hoʻonui ʻia ʻana o ka hopena i loko o nā mea maʻi me ka diabetes mellitus type 2 i hui pū ʻia me ka maʻi lālau kino, pono ai i ka hemodialysis, pono e hana me ka akahele.

Diagninide: Hōʻikeʻike

ʻO ka maʻi laʻi mellitus type 2 (me ka mālama ʻaʻai ʻole maikaʻi, hōʻemi ʻia a me ka hana kino) ma ka monotherapy a i hui pū ʻia me metformin a thiazolidinediones paha i nā hihia he hiki ʻole ke hoʻokō ʻoluʻolu i ka hoʻopiʻi glycemic puʻai me monotherapy me ka repaglinide a metformin a thiazolidinediones.

Diagninide: Nā Mana

- Kahi? A hypersensitivity i makemake ʻia i ka repaglinide a i ʻole kekahi o nā mea pono o ka lāʻau,

- ʻAno maʻi 'ai 1

- ʻO ka ketoacidosis Diabetes, maʻi kanesa precoma a me ka coma,

- Nā maʻi maʻi pāpaʻi, nā hōʻiliʻili nui a me nā kūlana ʻē aʻe e koi ai i ka ʻomo ʻana i ka insulin,

- Hoʻopilikia hōʻeha i ka hana ate,

- Ke hoʻonohonoho like ʻana o gemfibrozil (e ʻike i ka "Hoʻohui ʻana me nā lāʻau lapaʻau ʻē aʻe"),

- ka nele o ka Lactase, ka lactose intolerance, glucose-galactose malabsorption,

- ʻĀnō lohi a me ka lactation,

- Nā keiki a hiki i ka 18 mau makahiki.

ʻAʻole i hoʻokō ʻia nā haʻawina hauoli i nā maʻi ma lalo o nā makahiki 18 a ʻoi aku paha ma mua o 75 mau makahiki.

Me ka mālama pono (ka pono no ka mālama pono ʻana) pono e hana no ka hana lūlū o ka lewa a me ka maʻi maʻalahi, ka lolo, febrile syndrome, maʻi ʻole a me ke kūlohelohe, ʻona wai, ka maʻi nui, ka maʻi kino.

ʻŌpū a me ka lactation

ʻAʻole i hana ʻia nā haʻawina e pili ana i ka hoʻohana ʻana i ka repaglinide i nā wahine hāpai. No laila, ʻaʻole i aʻo ʻia ka palekana o ka repaglinide i nā wahine hāpai.

ʻ periodmeʻa

ʻAʻole i mālama ʻia nā haʻawina e pili ana i ka hoʻohana ʻana o ka repaglinide i nā wahine i ka wā o ka hoʻoulu ʻana. Inā pono e hoʻohana i ka lāʻau lapaʻau i ka wā o ka hoʻoulu ʻana, pono ka pale umauma.

ʻLoe a me ke kākele

Ua hōʻike ʻia ka lāʻau Diagnlinid ® ke ʻano he hoʻopili o ka mālama ʻana i ka papaʻai a me ka hana kino e hoʻemi i ka kaʻe o ka glucose i loko o ke koko, pono ka manawa e alakaʻi ai kāna alakaʻi.

Lawe ʻia ka lāʻau ma mua ma o ka papa nui o ka ʻaina 2, 3 a i ʻole he 4 i ka lā, ma ka 15 mau minuke ma mua o ka papaʻaina, akā hiki ke lawe ʻia i nā minuke mai 30 mau minuke ma mua o kahi pāʻina i ka manawa koke o ka ʻai ʻana.

Koho ʻia ka make o ka lāʻau no kēlā me kēia kanaka pākahi, e pili ana i ka paʻa o ka glucose i ke koko.

ʻO ka maʻa mua loa he 0.5 mg / lā (inā i lawe aku ka mea maʻi i kekahi lāʻau lapaʻau hypoglycemic waha - 1 mg). Hoʻololi ʻia ka hoʻoponopono ʻia o ka hana 1 i ka manawa i hoʻokahi pule a i ʻole 1 i ka manawa 2 ma ka hebedoma (ʻoiai e nānā ana i ka luhi o ka glucose i ke koko, ma ke ʻano he pane no ka pane ʻana i ka therapy). ʻO ka nui momona pālahalaha he 4 mg. ʻO ka nui loa ma kēlā me kēia lā he 16 mg.

Ka hoʻololi ʻana o nā mea maʻi me ka lāʻau maʻi me nā lāʻau lapaʻau hypoglycemic waha Hiki i ka hana maʻi Repaglinide hiki ke hana koke i ka manawa. Eia naʻe, ʻaʻole i hōʻike ʻia ka pilina kūpono ma waena o ka hopena o ka repaglinide a me ka nui o nā lāʻau hypoglycemic ʻē aʻe. ʻO ka paena mua ʻana i hoʻolilo ʻia i ka repaglinide i ka wā i lawe ʻia mai nā lāʻau lapaʻau hypoglycemic ʻē aʻe ma kahi o 1 mg ma mua o ka papa ʻai nui.

Hiki ke kuhikuhi i ka repaglinide me ka metformin a i ʻole thiazolidinediones i kahi o ka hiki ʻole o ka mālama ʻana i ka ʻaihue koko i ka monotherapy me ka metformin, thiazolidinediones a repaglinide paha. I kēia hihia, hoʻohana ʻia ke ʻano like o ka repaglinide e like me ka monotherapy. A laila e lawe i ka hoʻoponopono ʻia o kēlā me kēia lāʻau lāʻau e pili ana i ka loaʻa ʻana o ka glucose i loko o ke koko.

Nā hui ahonui kūikawā

(e nānā i ka ʻāpana "Nā Kūlana Kūʻokoʻa").

ʻAʻole ia e noʻonoʻo i hoʻohana i ka repaglinide no nā kānaka ma lalo o 18 mau makahiki ma muli o ka nele o ka ʻikepili i kona palekana a me ka hana i kēia pae o nā maʻi.

Diagninide: Loaʻa i nā ʻaoʻao

ʻO ka hopena maʻamau ka hypoglycemia, ka pinepine o ka mea, e like me kēlā me kēia ʻano maʻi mellitus therapy, ma luna o nā mea pilikino e like me ka ʻai ʻana, ka ʻano o ka laʻala, ka hana kino a me ke kaumaha.

ʻO nā hopena aʻe nā ʻaoʻao i nānā ʻia me ka hoʻohana ʻana i ka repaglinide a me nā mea hana waha e hoʻohālikelike i ka waha. Hoʻopili ʻia nā ʻaoʻao āpau e like me ka pinepine o ka hoʻolālā ʻana, i wehewehe ʻia: ka pinepine (≥1 / 100 a i ʻole

Me ka overdose, ulu ulu ka hypoglycemia.

Nā Hoʻomaka pōloli, māhuahua palupalu, palpitations, uhaki, hopohopo, hōʻeha, hōʻeha, ka huhū, ke kaumaha, ka wahaheʻe a me ka ʻike.

Ke hoʻohana nei i ka repaglinide i nā maʻi me ka diabetes mellitus type 2 i loko o hoʻokahi hebedoma e hoʻonui nui ʻia ʻo 4 i 20 mg 4 mau manawa i kahi lā (me kēlā me kēia pāʻina), nānā nui ʻia ka pili kokoke i 6 mau hebedoma, hōʻike ʻia e ka nui o ka hoʻohaʻahaʻa i ka glucose glucose me ka hoʻomohala ʻana i nā hōʻailona o ka hypoglycemia.

I ke kumu o nā hōʻailona o ka hypoglycemia, pono e hana ʻia nā hana kūpono e hoʻonui ai i ke kao o ka glucose i ke koko (e lawe i ka dextrose a i ʻole nā ​​meaʻai momona i nā kākena i loko). Ma ka hypoglycemia koʻikoʻi (ka nalowale o ka ʻike, coma), dextrose ke mālama ʻia i ka hana intravenously. Ma hope o ka hoʻihoʻi hou ʻana o ka ʻike - ke kau ʻana o ka mau momona i kālai ʻia (e pale i ka ulu ʻana o ka ulu ʻana o ka hypoglycemia).

Hoʻohui

Hiki i ka launa pū paha o ka repaglinide me nā lāʻau lapaʻau e pili ana i ka metabolism glucose.

ʻO ka metabolism, a no laila ke kūleʻa o ka repaglinide, hiki ke loli ma lalo o ke ʻano o nā lāʻau lapaʻau e koi ai, hana a hoʻokū paha i nā hana o nā enzyme mai ka hui o ka cytochrome P-450. E kiaʻi pono ka kiaʻi me ka hoʻokahuli o nā manawa CYP2C8 a me CYP3A4 inhibitors me ka repaglinide. Ua hōʻike nā haʻawina i ka hoʻokolohua ʻo Deferasirox, he mea nāwaliwali ikaika o CYP2C8 a me CYP3A4, a me ka repaglinide e alakaʻi i ka hoʻonui ʻana i ka hopena systemic o ka repaglinide, me ka hoʻohaʻahaʻa iki a nui naʻe i ka hoʻoliʻi ʻana o ka glucose koko. Me ka hoʻokolohua hui ʻole o Deferasirox a me Repaglinide, pono e noʻonoʻo i ka hōʻemi o ka hopena o Repaglinide a kiaʻi pono ai i ka ʻike o kaʻukala i loko o ke koko.

Me ka hoʻohana like ʻana o ka clopidogrel, ua ʻike ʻia kahi mea paʻa o kahi CYP2C8, a me ka repaglinide, he hoʻonui hoʻonui i ka systemic ka repaglinide a me kahi liʻiliʻi o ka hoʻokaʻina o ka glucose koko i nānā ʻia. Inā hoʻohana ʻia ka repaglinide a me ka clopidogrel i ka manawa like, e mālama pono ʻia ka nānā ʻana i ka glucose o ka glucose a me ka nānā ʻana i nā mea lapaʻau.

OATP1B1 anion transport protein inhibitors (e.g., cyclosporin) hiki ke hoʻonui hou i ka plasma repaglinide concentrations.

Hiki i nā lāʻau aʻe ke hoʻonui a / a e hoʻolōʻihi i ka hopena hypoglycemic o ka repaglinide:

ʻO Gemfibrozil, trimethoprim, rifampicin, clarithromycin, ketoconazole, itraconazole, cyclosporine, nā lāʻau lapaʻaka hypoglycemic, monoamine oxidase inhibitors, non-selective beta-adrenergic blocking agents, angiotensin e hoʻohuli ana i ka hoʻohui enzimator, salicylate, nonsteroidalide, nonsteroidalide

Hiki i nā beta-blockers ke uhi i nā hōʻailona o ka hypoglycemia.

ʻO ka hoʻokolohua ʻōpiopio o cimetidine, nifedipine a simvastatin (ʻo nā substrates CYP3A4) me ka repaglinide ʻaʻole koʻikoʻi i ke kīpili o ka papa lāʻau o ka repaglinide.

ʻAʻole pili ʻo Repaglinide i nā maʻi i ka maʻi pharmacokinetic o digoxin, theophylline, a i ʻole warfarin i ka wā i hoʻohana ʻia ai i nā mea hana olakino maikaʻi. No laila, ʻaʻohe mea pono o ka hoʻoponopono hoʻoponopono ʻia o kēia mau lāʻau inā hui pū me ka repaglinide.

Hiki i nā lāʻau lapaʻau ke hōʻemi i ka hopena hypoglycemic o ka repaglinide:

Contraceptives oral, rifampicin, barbiturates, carbamazepine, thiazides, glucocorticosteroids, danazole, hormones thyroid a sympathomimetics.

Hoʻohui pili nā hana hoʻohua (ethinyl estradiol / levonorgestrel) ʻaʻole ia i alakaʻi i ka loli koʻikoʻi ma o ka bioavailability o ka repaglinide holoʻokoʻa, ʻoiai ke hoʻokō nei ka pae o ka nui o ka repaglinide. ʻAʻole pili iki ʻo Repaglinide i ka bioavailability o ka levonorgestrel, akā hiki ke hopena ʻia kona hopena i ka bioavailability o ethinyl estradiol.

Ma kēia mea, i ka wā i koho a hiki paha i ke kāpae i nā lāʻau i luna, e loaʻa pono ana nā mea maʻi i ka repaglinide e nānā pono i nā manawa hewa o ka kaohi glycemic.

Nā ʻōlelo kikoʻī

Hōʻike ʻia ka Repaglinide no ka mālama mally glycemic a me ka hoʻomau ʻana o nā maʻi mellitus maʻi i ka wā o ka mālama ʻana i kaʻai, hoʻomaʻamaʻa, a me ka momona kaumaha.

ʻO ka mea ʻo ka repaglinide kahi lāʻau lapaʻau e hoʻoulu i ka huna ʻana i ka insulin, hiki iā ia ke hana i ka hypoglycemia. Me nā hui hoʻohui, hoʻonui i ka pilikia o ka hypoglycemia.

ʻO nā hōʻiliʻili nui a me nā mea hōʻeha, ʻoi loa ka wela, nā maʻi maʻi me ka febrile syndrome e koi ai i ka hoʻopau ʻana i nā lāʻau lapaʻau hypoglycemic waha a me ka hoʻokaʻawale ʻana i ka hoʻōla o ka insulin.

Pono e kiaʻi pinepine i ka nānāʻana o ka glucose i loko o ke koko ma kahi ʻōpū ʻole a ma hope o ka ʻai. Hoʻomaʻamaʻa ʻia ka mea maʻi e pili ana i ka hoʻonui ʻia ʻana o ka nui o ka hypoglycemia i nā hihia o ka inu ʻona, nā NSAID, i ka wā hoʻi wikiwiki ʻana.

Pono kahi hoʻoponopono hoʻoponopono ʻia no ke ʻano kūlohelohe a me ke kaumaha, kahi hoʻololi i ka ʻai.

I ka poʻe maʻi me ka maʻi palaka, a me ka poʻe maʻi e loaʻa ʻole i ka pōʻino, pono pono e mālama pono i ka wā e koho i ka mua a me ka mālama mālama ʻana, a me kona titration, i mea e pale ai i ka hypoglycemia.

Nā hui ahonui kūikawā

ʻO ka koho ʻana i ka maʻi maʻi ma nā maʻi me ka maʻi diabetes type 2 i hui pū ʻia me ka hana ʻino ʻole ʻoi loa ka mea e hana ʻia.

ʻO ka hoʻokō o nā hana maʻamau o ka repaglinide i loko o nā mea maʻi me ka hana aho maʻemaʻe e hiki ke alakaʻi i kahi kiʻekiʻe o ka repaglinide a me nā metabolites ma mua o nā mea maʻi me nā hana ate maʻamau. Ma kēia noʻonoʻo, ua hoʻohālikelike ʻia ke koho hou ʻana o ka repaglinide i ka poʻe maʻi me ka hōʻeha ʻana i ka maʻi hepatic (e nānā i ka ʻāpana "Contraindications"), a i nā mea maʻi me ka hana hepatic hauʻoliʻa o ka pale a me ka repaglinide e pono e hoʻohana me ka akahele. Pono hoʻi e hoʻonui pono ʻia ka pae ma waena o ka hoʻoponopono o ka hoʻoponopono ʻana i ka pane ʻana i ka pane.

Hoʻokomo i ka hiki ke alakaʻi i nā kaʻa a hana me nā mīkini

Hiki i ka poʻe maʻi ke nānā i ka helu a me ka hopena i ka wā o ka hypoglycemia a me ka hyperglycemia, he mea hiki ke pilikia i nā kūlana e pono ai kēia mana (no ka laʻana, ke kaʻi aku nei i nā kaʻa a hana paha me nā mīkini a me nā mīkini. Pono e paipai ʻia nā mea maʻi e hana i nā hana e pale ai i ka hoʻomohala ʻana o ka hypoglycemia a me ka hyperglycemia i ka wā e hoʻokele ana i nā kaʻa a hana pū me nā hana like. He mea koʻikoʻi loa kēia no nā poʻe maʻi me ka ʻole a hōʻemi iki paha i nā hōʻailona o nā mea hana mua i ka hoʻomohala ʻana i ka hypoglycemia a i ʻole mau manawa pinepine o ka hypoglycemia. I kēia mau hihia, pono e noʻonoʻo ʻia ka hiki ʻana o ia mau hana.

Nā hōʻailona a me nā contraindications

E like me nā lāʻau lapaʻau ʻē aʻe, aia ʻo Diclinid i kāna mau ʻike pono no ka hoʻohana ʻana. E like me ka mea i ʻōlelo ʻia ma luna, ua kuhikuhi ʻia e kau i nā maʻi maʻi II e hoʻomaʻamaʻa i ke kō koko koko. Hāʻawi ʻia i nā hana i hoʻokau mua ʻia ma ke ʻano o nā meaʻai a me nā haʻuki i hāʻawi i ka hopena therapeutic i koi ʻia.

ʻAʻole hiki iā ʻoe ke lawe i ka lāʻau lapaʻau inā he maʻi hypersensitivity o ka mea maʻi i ke ʻano he nui a i ʻole nā ​​mea ʻona, e hiki ai i kēia ke alakaʻi i kahi maʻi kūlohelohe o nā ʻano paʻakikī.

ʻAʻole kuhikuhi ʻia ka lāʻau lapaʻau no ka mālama ʻana i ka maʻi mellitus o ka maʻi kuʻuna, me ka ʻano maʻi diabetes o ka ketoacidosis, ke kūlana precomatous, coma, hana aho ʻole, lactase deficiency, mālama i ka lactose.

ʻAʻole liʻiliʻi ka papa inoa o nā contraindications a ua komo i nā ʻano aʻe:

• ʻO ka wā o ka hōʻeha, ka umauma.
• ʻO nā makahiki o nā keiki, ʻo ia hoʻi a hiki i ka 18 mau makahiki.
• ʻAʻole hiki iā ʻoe ke hoʻohui i ka lāʻau me ka gemfibrozil.
• ʻO ka maʻi nui.
• Nā ʻōhua kino.
• Nā hōʻeha ʻeha like ʻole.

Pono loa nā contraindications i ʻōlelo ʻia ma luna nei. I nā huaʻōlelo ʻē aʻe, ʻaʻole i kuhikuhi mua ʻia ka lāʻau lapaʻau inā loaʻa iā lākou ka mōʻaukala o ka mea maʻi. E pili pū me lākou, hoʻokaʻawale ʻia nā contraindications pili.

ʻO kēia ka mea ma mua o ke kau ʻana i kahi lāʻau lapaʻau, hoʻohālikelike ke kauka i ka hopena o ka hopena o ka hopena a me ka hōʻeha ʻana o nā hopena ʻokoʻa a me nā ʻōmole ʻē aʻe.

Pākuʻi ʻia nā contraindications e pili ana i ka huaʻu febrile, kahi ʻano maʻamau o ka hana ʻole o ka pilikia, ka ʻole o ka palaka, ke ʻano maʻamau o ka ʻalaka, a me ke ʻano maʻamau o ka mea maʻi.

Ua hala ke lāʻau i nā hoʻokolohua lapaʻau āpau. Eia naʻe, ʻike ʻia nā noi ʻana a hiki i ka makahiki 18 a ʻoi aku ʻo 75 he nui.

Hiki i nā maʻi ʻinoʻino mai ka hoʻohana ʻana i ka lāʻau lapaʻau

Hoʻomaopopo nā loiloi o nā mea maʻi e kōkua koke ka lāʻau lapaʻau i ka hoʻemi ʻana i ke kō o ka wai me ka hoʻomaikaʻi maikaʻi. Me kēia, nui nā kamaʻilio e pili ana i nā hopena ʻaoʻao i lilo i ka hopena o ka hoʻohana ʻana i ka lāʻau.

ʻO ka hopena maʻamau e pili ana i kahi kūlana hypoglycemic. Eia naʻe, aneane hiki ʻole ke pale i ka emi ʻana o ke kō. ʻOiai ke ʻano nui nei kēia ʻano: ka nui o ka lāʻau lapaʻau, kaʻai, ka hana kino, ke ʻano koʻikoʻi, neurosis, nā manaʻo ikaika, etc.

Hiki ke hopena nā hopena ʻaoʻao i ka ʻaoʻao o nā kaʻina metabolic: e like me ka mea i hoʻomaopopo ai, ʻo ia ka hypoglycemia mua. Ma ke kānāwai, ua lawa ka lawe ʻana i nā koina liʻiliʻi i ka maʻamau o ka mālama pono o ka mea maʻi. Ma waho aʻe o nā hihia kaila, hiki i ka nānā koke ke nānā aku.

Ke hōʻike nei ʻo Abstract o ka lāʻau lapaʻau i nā hopena hope loa:

1. Ma ka ʻāpana o ka ʻōnaehana: ka laulima ma ke ʻano he ʻano neʻe, no ka laʻana vasculitis, nā hopena kūlohelohe me nā ʻōmaka o ke kino - ʻūhā, ʻeha, ʻulaʻula o ka ʻili.
2. ʻO ka hoʻopauʻoleʻana o ka hanu a me ka gastrointestinal tract, ka ʻeha ma ka ʻōpū, ka hōʻeu ʻana o ka nausea a me ka luaʻi.
3. ʻO ka hana e hoʻonui ai i nā kinemona o ka ate, ka hana a ka nānā i ke aho.

Hoʻomaopopo ka lawe ʻana i ka lāʻau i hiki ke hoʻonāukiuki i ka nānā aku.

Ma ke ʻano he kānāwai, he pōkole kēia, hōʻoluʻoluʻoki i ka wā o ka hoʻomehana. Ma waho aʻe paha i nā hihia kaila, pono ka haʻalele ʻana i ka lāʻau lapaʻau.

Nā ʻōkuhi no ka hoʻohana

ʻO ka lāʻau lapaʻau Diclinid ʻaʻole panacea, he mea hoʻohui ia i ka hana pilikino a me ka pāʻai haʻahaʻa-ambany no ka maʻi maʻi. Ma kēia hihia wale nō e hiki ke hoʻokō ʻia ka hopena therapeutic o ka hopena.

Ua koho mau ʻia ka hewa o ka lāʻau. ʻO ka ʻōlelo nui ka hōʻailona mua o ka haki koko. Ke koho nei i kahi maʻa, nā maʻi concomitant a me nā mea ʻē aʻe i hoʻohui pū ʻia i ka waihona.

ʻO nā ʻōlelo e hoʻohana ai e pono e lawe i nā papa i ka hapaha o ka hola ma mua o ka papa ʻaina nui. Akā, hiki iā ʻoe ke lawe i ka hapalua hola ma mua o kahi pāʻina.

Nā hiʻohiʻona o ka maʻi ma o Diagninid:

• ʻO ka maʻa maʻi maʻamau no nā poʻe maʻi ʻaʻole i lawe i nā pōpoki e hoʻohaʻahaʻa i ke kōkē o ke koko i ka maʻi diabetes type 2 he 0.5 mg.
• Inā ua lawe mua ka mea maʻi i kekahi lawehala hypoglycemic ma mua, a laila ka helu mua ma mua o 1 mg.
• E like me ka mea e hiki ai, e ʻae ʻia e hoʻoponopono i ka hopena o ka lāʻau i hoʻokahi manawa i kēlā me kēia lā 7-14.
• Ma ke ʻano he kaukaukau, ma hope o nā piʻi a pau, ʻo ke ʻano maʻamau ka 4 mg o ka lāʻau lapaʻau, ka mea i hoʻokaʻawale ʻia i ʻekolu mau pona i kēlā me kēia lā.
• ʻO ka nui loa o ka lāʻau o ka lāʻau he 16 mg.

Inā lawe ka mea maʻi i kahi lawena hypoglycemic hou a pono e hoʻololi ʻia no kekahi kumu olakino, a laila lawe ʻia ka hoʻololi iā Diagninid me nā wā ʻole. ʻOiai no ka hiki ʻole ke hoʻonohonoho pono i ka pālahalaha kūpono ma waena o nā lāʻau ʻelua, akā ʻo ka dosis mua ʻaʻole iʻoi aku ma mua o 1 mg.

Mālama ʻia nā palapala i kākau ʻia ma kahi o ke ʻano o ka hoʻokele ʻana o ka lāʻau lapaʻau. Ma keʻano pilikino, ma ka monotherapy a me ka hoʻomehana ʻia ʻana o ka maʻi type o ka maʻi mellitus type 2. ʻO ke kumukūʻai mai ke 200 rubles.

Nā kikowaena o Diaglinide, nā kumukūʻai a me nā loiloi

He liʻiliʻi nā liʻiliʻi o Diaglinide, a ʻo NovoNorm a me Repaglinide, ua ʻōlelo ʻia iā lākou. Hoʻololi ke kumukūʻai o NovoNorm mai 170 a 250 rubles. Hiki ke kūʻai ʻia nā lāʻau lapaʻau i loko o ka lāʻau kūʻai a i ʻole ka laiki kiosk, hiki iā ia ke kūʻai aku i nā lāʻau lapaʻau ma ka Pūnaewele.

Mālama ʻia ka lāʻau lapaʻau i kahi wahi pouli, ʻaʻole hiki i nā keiki liʻiliʻi. ʻO ʻelua mau makahiki ka noho o ke ola o ka lāʻau.

Ma hope o ka nānā ʻana i ka loiloi o nā loiloi nui o ka maʻi maʻi, hiki iā mākou ke manaʻo i ka hoʻopaʻa pono ʻana o ka lāʻau me ka hana, kōkua i ka hoʻāoʻi ʻana i ke kō. Eia nō naʻe, koi ka mea maʻi i nā hana ma ke ʻano o ka meaʻai a me ka hana kino.

Aia kekahi hewa hewa maikaʻi, ke hoʻopiʻi nui ʻia e ka hoʻopaʻi ʻole ʻana i ka pauku i ʻōlelo ʻia ai, ʻo ia hoʻi nā hewa i ka ʻai.

A he aha kāu e haʻi ai no kēia lāʻau lapaʻau? Ua lawe ʻoe i nā pil, a pehea i hana ai lākou i kou kūlana?